You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarteolol
Accession NumberDB00521  (APRD00195)
TypeSmall Molecule
GroupsApproved
DescriptionA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. [PubChem]
Structure
Thumb
Synonyms
Carteolol
Carteololum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carteolol Hydrochloridesolution/ drops10 mg/mLophthalmicBausch & Lomb Incorporated2000-01-20Not applicableUs
Carteolol Hydrochloridesolution/ drops10 mg/mLophthalmicMedsource Pharmaceuticals2000-01-20Not applicableUs
Carteolol Hydrochloridesolution10 mg/mLophthalmicSandoz Inc.2000-01-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CartrolNot Available
EndakRottapharm/Madaus
OcupressNovartis
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Carteolol Hydrochloride
51781-21-6
Thumb
  • InChI Key: FYBXRCFPOTXTJF-UHFFFAOYNA-N
  • Monoisotopic Mass: 328.155370383
  • Average Mass: 328.834
DBSALT000319
Categories
UNII8NF31401XG
CAS number51781-06-7
WeightAverage: 292.3734
Monoisotopic: 292.178692644
Chemical FormulaC16H24N2O3
InChI KeyInChIKey=LWAFSWPYPHEXKX-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
IUPAC Name
5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydroquinolin-2-one
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinolones and derivatives
Direct ParentHydroquinolones
Alternative Parents
Substituents
  • Tetrahydroquinolone
  • Tetrahydroquinoline
  • Alkyl aryl ether
  • Benzenoid
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Lactam
  • Carboxamide group
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of intraocular hypertension and chronic open-angle glaucoma
PharmacodynamicsCarteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
Mechanism of actionThe primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

SubstrateEnzymesProduct
Carteolol
8-HydroxycarteololDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityThe most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Carteolol Action PathwayDrug actionSMP00658
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier-0.5578
Caco-2 permeable-0.6897
P-glycoprotein substrateSubstrate0.9025
P-glycoprotein inhibitor INon-inhibitor0.6539
P-glycoprotein inhibitor IINon-inhibitor0.9197
Renal organic cation transporterNon-inhibitor0.8058
CYP450 2C9 substrateNon-substrate0.7911
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.59
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7633
Ames testNon AMES toxic0.8024
CarcinogenicityNon-carcinogens0.9099
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4801 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9902
hERG inhibition (predictor II)Non-inhibitor0.5237
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
  • Bausch and lomb inc
  • Novex pharma
  • Novartis pharmaceuticals corp
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Solutionophthalmic10 mg/mL
Solution/ dropsophthalmic10 mg/mL
Prices
Unit descriptionCostUnit
Carteolol HCl 1% Solution 15ml Bottle57.82USD bottle
Carteolol HCl 1% Solution 10ml Bottle38.55USD bottle
Carteolol HCl 1% Solution 5ml Bottle22.13USD bottle
Carteolol hcl 1% eye drops3.93USD ml
Cartrol 2.5 mg tablet1.37USD tablet
Cartrol 5 mg tablet1.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.421 mg/mLALOGPS
logP1.05ALOGPS
logP1.42ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)13.41ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.59 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity83.14 m3·mol-1ChemAxon
Polarizability32.79 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Tamura,Y., Nakagawa,K., Yoshizaki,S.and Murakami,N.; U.S.Patent 3,910,924; October 7,
1975; assigned to Otsuka Pharmaceutical Co., Ltd.

General References
  1. El-Kamel A, Al-Dosari H, Al-Jenoobi F: Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan-Feb;13(1):55-9. [PubMed:16401594 ]
  2. Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A: Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea. 2005 Mar;24(2):213-20. [PubMed:15725891 ]
  3. Trinquand C, Romanet JP, Nordmann JP, Allaire C: [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. J Fr Ophtalmol. 2003 Feb;26(2):131-6. [PubMed:12660585 ]
External Links
ATC CodesS01ED55S01ED05C07AA15
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Carteolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Carteolol.
AbirateroneThe metabolism of Carteolol can be decreased when combined with Abiraterone.
AcebutololCarteolol may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Carteolol.
AcepromazineAcepromazine may increase the hypotensive activities of Carteolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Carteolol is combined with Acetazolamide.
AcetohexamideCarteolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Carteolol is combined with Acetylcholine.
AcetyldigitoxinCarteolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Carteolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Carteolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Carteolol.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Carteolol.
AlfuzosinCarteolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Carteolol.
AliskirenCarteolol may increase the hypotensive activities of Aliskiren.
AlprenololCarteolol may increase the hypotensive activities of Alprenolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Carteolol.
AmbrisentanCarteolol may increase the hypotensive activities of Ambrisentan.
AmifostineCarteolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Carteolol is combined with Amiloride.
AminophyllineCarteolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Carteolol.
AmlodipineAmlodipine may increase the hypotensive activities of Carteolol.
AmobarbitalAmobarbital may increase the hypotensive activities of Carteolol.
AmodiaquineThe metabolism of Carteolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Carteolol can be increased when it is combined with Amoxapine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Carteolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Carteolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Carteolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Carteolol is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Carteolol.
ArbutamineCarteolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Carteolol is combined with Arecoline.
ArformoterolCarteolol may decrease the bronchodilatory activities of Arformoterol.
AripiprazoleAripiprazole may increase the hypotensive activities of Carteolol.
ArtemetherThe metabolism of Carteolol can be decreased when combined with Artemether.
AtenololAtenolol may increase the hypotensive activities of Carteolol.
AtomoxetineThe metabolism of Carteolol can be decreased when combined with Atomoxetine.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Carteolol.
AzelastineAzelastine may decrease the antihypertensive activities of Carteolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Carteolol is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the antihypertensive activities of Carteolol.
BambuterolCarteolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Carteolol.
BenazeprilCarteolol may increase the hypotensive activities of Benazepril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Carteolol.
BenmoxinBenmoxin may increase the hypotensive activities of Carteolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Carteolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
BepridilCarteolol may increase the hypotensive activities of Bepridil.
BeractantCarteolol may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Carteolol.
BethanecholThe risk or severity of adverse effects can be increased when Carteolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Carteolol.
BimatoprostCarteolol may increase the hypotensive activities of Bimatoprost.
BisoprololCarteolol may increase the hypotensive activities of Bisoprolol.
BosentanCarteolol may increase the hypotensive activities of Bosentan.
BretyliumBretylium may increase the bradycardic activities of Carteolol.
BretyliumCarteolol may increase the hypotensive activities of Bretylium.
BrimonidineCarteolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Carteolol.
BromfenacBromfenac may decrease the antihypertensive activities of Carteolol.
BromocriptineCarteolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Carteolol.
BumetanideThe risk or severity of adverse effects can be increased when Carteolol is combined with Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Carteolol.
BupranololCarteolol may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Carteolol can be decreased when combined with Bupropion.
CabergolineCarteolol may increase the vasoconstricting activities of Cabergoline.
CalfactantCarteolol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Carteolol is combined with Canagliflozin.
CandesartanCarteolol may increase the hypotensive activities of Candesartan.
CandoxatrilCarteolol may increase the hypotensive activities of Candoxatril.
CaptoprilCarteolol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Carteolol is combined with Carbachol.
CaroxazoneCaroxazone may increase the hypotensive activities of Carteolol.
CarprofenCarprofen may decrease the antihypertensive activities of Carteolol.
CarvedilolCarteolol may increase the hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Carteolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Carteolol.
CeliprololCeliprolol may increase the hypotensive activities of Carteolol.
CeliprololCarteolol may decrease the bronchodilatory activities of Celiprolol.
CeritinibCarteolol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Carteolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Carteolol.
ChlorothiazideCarteolol may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Carteolol.
ChlorpropamideCarteolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Carteolol.
CholecalciferolThe metabolism of Carteolol can be decreased when combined with Cholecalciferol.
CilazaprilCarteolol may increase the hypotensive activities of Cilazapril.
CimetidineThe metabolism of Carteolol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Carteolol can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Carteolol can be decreased when combined with Citalopram.
ClemastineThe metabolism of Carteolol can be decreased when combined with Clemastine.
ClenbuterolCarteolol may decrease the bronchodilatory activities of Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.
ClobazamThe metabolism of Carteolol can be decreased when combined with Clobazam.
ClomipramineThe serum concentration of Carteolol can be increased when it is combined with Clomipramine.
ClonidineCarteolol may increase the hypotensive activities of Clonidine.
ClonixinClonixin may decrease the antihypertensive activities of Carteolol.
ClotrimazoleThe metabolism of Carteolol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Carteolol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Carteolol can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Carteolol can be decreased when combined with Cocaine.
CoumaphosCoumaphos may increase the bradycardic activities of Carteolol.
CrizotinibCarteolol may increase the bradycardic activities of Crizotinib.
CryptenamineCarteolol may increase the hypotensive activities of Cryptenamine.
CyclothiazideCarteolol may increase the hypotensive activities of Cyclothiazide.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Carteolol.
DapagliflozinThe risk or severity of adverse effects can be increased when Carteolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Carteolol can be increased when it is combined with Dapoxetine.
DarifenacinThe metabolism of Carteolol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Carteolol can be increased when it is combined with Darunavir.
DebrisoquinCarteolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Carteolol.
DelavirdineThe metabolism of Carteolol can be decreased when combined with Delavirdine.
DemecariumDemecarium may increase the bradycardic activities of Carteolol.
DeserpidineCarteolol may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Carteolol can be decreased when combined with Desipramine.
DeslanosideCarteolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineThe risk or severity of adverse effects can be increased when Carteolol is combined with Dexmedetomidine.
DiazoxideDiazoxide may increase the hypotensive activities of Carteolol.
DichlorvosDichlorvos may increase the bradycardic activities of Carteolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Carteolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Carteolol is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Carteolol.
DigitoxinCarteolol may increase the bradycardic activities of Digitoxin.
DigoxinCarteolol may increase the bradycardic activities of Digoxin.
DihydroergotamineCarteolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
DiltiazemDiltiazem may increase the hypotensive activities of Carteolol.
DinutuximabThe risk or severity of adverse effects can be increased when Carteolol is combined with Dinutuximab.
DiphenhydramineThe metabolism of Carteolol can be decreased when combined with Diphenhydramine.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Carteolol.
DipivefrinCarteolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Carteolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Carteolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Carteolol.
DobutamineCarteolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Carteolol.
DorzolamideCarteolol may increase the hypotensive activities of Dorzolamide.
DoxazosinCarteolol may increase the hypotensive activities of Doxazosin.
DronedaroneCarteolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Carteolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Carteolol.
DroxidopaCarteolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetineCarteolol may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Carteolol can be decreased when combined with Duloxetine.
DyphyllineCarteolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Carteolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Carteolol.
EfonidipineCarteolol may increase the hypotensive activities of Efonidipine.
EliglustatThe metabolism of Carteolol can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Carteolol is combined with Empagliflozin.
EnalaprilCarteolol may increase the hypotensive activities of Enalapril.
EnalaprilatCarteolol may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Carteolol.
EphedraCarteolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Carteolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Carteolol.
EpinephrineCarteolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Carteolol.
EplerenoneThe risk or severity of adverse effects can be increased when Carteolol is combined with Eplerenone.
EpoprostenolCarteolol may increase the hypotensive activities of Epoprostenol.
EprosartanCarteolol may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateCarteolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineCarteolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineCarteolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Carteolol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Carteolol is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Carteolol.
EtodolacEtodolac may decrease the antihypertensive activities of Carteolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Carteolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Carteolol.
EtoperidoneThe serum concentration of Carteolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Carteolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Carteolol.
exisulindexisulind may decrease the antihypertensive activities of Carteolol.
FelodipineCarteolol may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Carteolol.
FenfluramineThe serum concentration of Carteolol can be increased when it is combined with Fenfluramine.
FenoldopamCarteolol may increase the hypotensive activities of Fenoldopam.
FenoprofenFenoprofen may decrease the antihypertensive activities of Carteolol.
FenoterolCarteolol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Carteolol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carteolol.
FingolimodCarteolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Carteolol.
FlunixinFlunixin may decrease the antihypertensive activities of Carteolol.
FluoxetineThe serum concentration of Carteolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Carteolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Carteolol.
FluvoxamineThe metabolism of Carteolol can be decreased when combined with Fluvoxamine.
FormoterolCarteolol may decrease the bronchodilatory activities of Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Carteolol.
FurazolidoneFurazolidone may increase the hypotensive activities of Carteolol.
FurosemideThe risk or severity of adverse effects can be increased when Carteolol is combined with Furosemide.
GalantamineGalantamine may increase the bradycardic activities of Carteolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Carteolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Carteolol.
GlibornurideCarteolol may increase the hypoglycemic activities of Glibornuride.
GliclazideCarteolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideCarteolol may increase the hypoglycemic activities of Glimepiride.
GlipizideCarteolol may increase the hypoglycemic activities of Glipizide.
GliquidoneCarteolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideCarteolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideCarteolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Carteolol is combined with GTS-21.
GuanabenzCarteolol may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Carteolol.
GuanethidineCarteolol may increase the hypotensive activities of Guanethidine.
GuanfacineCarteolol may increase the hypotensive activities of Guanfacine.
HaloperidolThe metabolism of Carteolol can be decreased when combined with Haloperidol.
HexamethoniumCarteolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Carteolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Carteolol.
Huperzine AHuperzine A may increase the bradycardic activities of Carteolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Carteolol.
HydralazineCarteolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideCarteolol may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideCarteolol may increase the hypotensive activities of Hydroflumethiazide.
HydroxychloroquineThe metabolism of Carteolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Carteolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Carteolol.
IcatibantIcatibant may decrease the antihypertensive activities of Carteolol.
IloprostIloprost may increase the hypotensive activities of Carteolol.
ImipramineThe metabolism of Carteolol can be decreased when combined with Imipramine.
IndacaterolCarteolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Carteolol can be increased when it is combined with Indalpine.
IndapamideCarteolol may increase the hypotensive activities of Indapamide.
IndenololCarteolol may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Carteolol can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Carteolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Carteolol.
IndoraminCarteolol may increase the hypotensive activities of Indoramin.
Insulin PorkCarteolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Carteolol.
IproniazidIproniazid may increase the hypotensive activities of Carteolol.
IrbesartanCarteolol may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Carteolol.
IsoetarineCarteolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Carteolol.
IsoniazidThe metabolism of Carteolol can be decreased when combined with Isoniazid.
IsoprenalineCarteolol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Carteolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Carteolol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Carteolol.
IvabradineCarteolol may increase the bradycardic activities of Ivabradine.
KebuzoneKebuzone may decrease the antihypertensive activities of Carteolol.
KetoconazoleThe metabolism of Carteolol can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Carteolol.
KetorolacKetorolac may decrease the antihypertensive activities of Carteolol.
LabetalolCarteolol may increase the hypotensive activities of Labetalol.
LacidipineCarteolol may increase the hypotensive activities of Lacidipine.
LacosamideCarteolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideCarteolol may increase the bradycardic activities of Lanreotide.
LatanoprostCarteolol may increase the hypotensive activities of Latanoprost.
LeflunomideLeflunomide may decrease the antihypertensive activities of Carteolol.
LercanidipineCarteolol may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Carteolol is combined with Levobunolol.
LevodopaCarteolol may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe serum concentration of Carteolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Carteolol.
LisinoprilCarteolol may increase the hypotensive activities of Lisinopril.
LobelineThe risk or severity of adverse effects can be increased when Carteolol is combined with Lobeline.
LofexidineCarteolol may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Carteolol can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Carteolol can be decreased when combined with Lorcaserin.
LornoxicamLornoxicam may decrease the antihypertensive activities of Carteolol.
LosartanCarteolol may increase the hypotensive activities of Losartan.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Carteolol.
Lu AA21004The serum concentration of Carteolol can be increased when it is combined with Lu AA21004.
LucinactantCarteolol may increase the bradycardic activities of Lucinactant.
LumefantrineThe metabolism of Carteolol can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Carteolol.
MacitentanCarteolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Carteolol.
MalathionMalathion may increase the bradycardic activities of Carteolol.
ManidipineCarteolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Carteolol is combined with Mannitol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Carteolol.
MebanazineMebanazine may increase the hypotensive activities of Carteolol.
MecamylamineCarteolol may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Carteolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Carteolol.
MefloquineMefloquine may increase the bradycardic activities of Carteolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Carteolol.
MemantineMemantine may increase the bradycardic activities of Carteolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Carteolol.
MesalazineMesalazine may decrease the antihypertensive activities of Carteolol.
MesoridazineMesoridazine may increase the hypotensive activities of Carteolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Carteolol.
MethacholineThe risk or severity of adverse effects can be increased when Carteolol is combined with Methacholine.
MethadoneThe metabolism of Carteolol can be decreased when combined with Methadone.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
MethazolamideThe risk or severity of adverse effects can be increased when Carteolol is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Carteolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Carteolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol.
MethyldopaCarteolol may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Carteolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Carteolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Carteolol.
MetipranololCarteolol may increase the hypotensive activities of Metipranolol.
MetolazoneCarteolol may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Carteolol.
MibefradilCarteolol may increase the hypotensive activities of Mibefradil.
MidodrineCarteolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Carteolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Carteolol.
MinoxidilMinoxidil may increase the hypotensive activities of Carteolol.
MirabegronThe metabolism of Carteolol can be decreased when combined with Mirabegron.
MoclobemideMoclobemide may increase the hypotensive activities of Carteolol.
MoexiprilCarteolol may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Carteolol.
MoricizineMoricizine may increase the hypotensive activities of Carteolol.
MoxonidineCarteolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Carteolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Carteolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Carteolol.
NadololCarteolol may increase the hypotensive activities of Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Carteolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.
NaproxenNaproxen may decrease the antihypertensive activities of Carteolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Carteolol.
NebivololCarteolol may increase the hypotensive activities of Nebivolol.
NeostigmineNeostigmine may increase the bradycardic activities of Carteolol.
NepafenacNepafenac may decrease the antihypertensive activities of Carteolol.
NesiritideThe risk or severity of adverse effects can be increased when Carteolol is combined with Nesiritide.
NevirapineThe metabolism of Carteolol can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Carteolol.
NicardipineCarteolol may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Carteolol.
NicotineThe risk or severity of adverse effects can be increased when Carteolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Carteolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Carteolol.
NifedipineThe risk or severity of adverse effects can be increased when Carteolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Carteolol.
NiguldipineCarteolol may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Carteolol can be decreased when combined with Nilotinib.
NilvadipineCarteolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Carteolol.
NimodipineNimodipine may increase the hypotensive activities of Carteolol.
NisoldipineNisoldipine may increase the hypotensive activities of Carteolol.
NitrendipineCarteolol may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Carteolol is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Carteolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Carteolol.
NorepinephrineCarteolol may decrease the bronchodilatory activities of Norepinephrine.
ObinutuzumabCarteolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Carteolol.
OctreotideOctreotide may increase the bradycardic activities of Carteolol.
OlanzapineThe serum concentration of Carteolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Carteolol.
OlodaterolCarteolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Carteolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Carteolol.
OmapatrilatCarteolol may increase the hypotensive activities of Omapatrilat.
OrciprenalineCarteolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Carteolol.
OuabainCarteolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Carteolol.
OxprenololCarteolol may increase the hypotensive activities of Oxprenolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Carteolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.
PanobinostatThe metabolism of Carteolol can be decreased when combined with Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Carteolol is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Carteolol.
PargylineCarteolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Carteolol can be increased when it is combined with Paroxetine.
PasireotideCarteolol may increase the bradycardic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololCarteolol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Carteolol.
PentoliniumCarteolol may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Carteolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Carteolol.
PerindoprilCarteolol may increase the hypotensive activities of Perindopril.
PerphenazinePerphenazine may increase the hypotensive activities of Carteolol.
PhenelzinePhenelzine may increase the hypotensive activities of Carteolol.
PheniprazinePheniprazine may increase the hypotensive activities of Carteolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Carteolol.
PhenoxybenzamineCarteolol may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Carteolol.
PhentolamineCarteolol may increase the hypotensive activities of Phentolamine.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Carteolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
PhenylpropanolamineCarteolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Carteolol.
PilocarpineThe risk or severity of adverse effects can be increased when Carteolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Carteolol.
PinacidilCarteolol may increase the hypotensive activities of Pinacidil.
PindololCarteolol may increase the hypotensive activities of Pindolol.
PirbuterolCarteolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Carteolol.
PirlindolePirlindole may increase the hypotensive activities of Carteolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Carteolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Carteolol.
PolythiazideCarteolol may increase the hypotensive activities of Polythiazide.
Poractant alfaCarteolol may increase the bradycardic activities of Poractant alfa.
PrazosinPrazosin may increase the hypotensive activities of Carteolol.
PrimaquineThe metabolism of Carteolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Carteolol.
ProcaterolCarteolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Carteolol.
PromazinePromazine may increase the hypotensive activities of Carteolol.
PromethazinePromethazine may increase the hypotensive activities of Carteolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Carteolol.
PropafenoneThe serum concentration of Carteolol can be increased when it is combined with Propafenone.
PropafenoneCarteolol may increase the bradycardic activities of Propafenone.
PropranololCarteolol may increase the hypotensive activities of Propranolol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Carteolol.
PTC299PTC299 may decrease the antihypertensive activities of Carteolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Carteolol.
QuetiapineThe risk or severity of adverse effects can be increased when Carteolol is combined with Quetiapine.
QuinaprilCarteolol may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Carteolol can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Carteolol.
RamiprilRamipril may increase the hypotensive activities of Carteolol.
RanolazineThe metabolism of Carteolol can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Carteolol.
RegorafenibRegorafenib may increase the bradycardic activities of Carteolol.
RemikirenRemikiren may increase the hypotensive activities of Carteolol.
RescinnamineCarteolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Carteolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Carteolol.
RiociguatCarteolol may increase the hypotensive activities of Riociguat.
RisperidoneCarteolol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.
RitodrineCarteolol may decrease the bronchodilatory activities of Ritodrine.
RitonavirThe metabolism of Carteolol can be decreased when combined with Ritonavir.
RituximabCarteolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Carteolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Carteolol.
RolapitantThe metabolism of Carteolol can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Carteolol can be decreased when combined with Ropinirole.
RuxolitinibRuxolitinib may increase the bradycardic activities of Carteolol.
SafrazineSafrazine may increase the hypotensive activities of Carteolol.
SalbutamolCarteolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Carteolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Carteolol.
SalmeterolCarteolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Carteolol.
SaprisartanCarteolol may increase the hypotensive activities of Saprisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Carteolol.
SelegilineSelegiline may increase the hypotensive activities of Carteolol.
SelexipagCarteolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Carteolol.
SertralineThe serum concentration of Carteolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Carteolol.
SilodosinCarteolol may increase the orthostatic hypotensive activities of Silodosin.
SitaxentanCarteolol may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Carteolol.
SpiraprilCarteolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Carteolol.
SRT501SRT501 may decrease the antihypertensive activities of Carteolol.
StiripentolThe metabolism of Carteolol can be decreased when combined with Stiripentol.
SufentanilCarteolol may increase the bradycardic activities of Sufentanil.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Carteolol.
SulindacSulindac may decrease the antihypertensive activities of Carteolol.
SuprofenSuprofen may decrease the antihypertensive activities of Carteolol.
TacrineTacrine may increase the bradycardic activities of Carteolol.
TadalafilTadalafil may increase the antihypertensive activities of Carteolol.
TamsulosinCarteolol may increase the orthostatic hypotensive activities of Tamsulosin.
TelmisartanCarteolol may increase the hypotensive activities of Telmisartan.
TemocaprilCarteolol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Carteolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Carteolol.
TerazosinThe risk or severity of adverse effects can be increased when Carteolol is combined with Terazosin.
TerbinafineThe metabolism of Carteolol can be decreased when combined with Terbinafine.
TerbutalineCarteolol may decrease the bronchodilatory activities of Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Carteolol.
TerlipressinCarteolol may increase the hypotensive activities of Terlipressin.
TheophyllineCarteolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Carteolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Carteolol.
ThiopentalThiopental may increase the hypotensive activities of Carteolol.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Carteolol.
ThioridazineThioridazine may increase the hypotensive activities of Carteolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Carteolol.
TiboloneCarteolol may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Carteolol can be decreased when combined with Ticlopidine.
TicrynafenCarteolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Carteolol.
TipranavirThe metabolism of Carteolol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Carteolol is combined with Tizanidine.
TofacitinibTofacitinib may increase the bradycardic activities of Carteolol.
TolazamideCarteolol may increase the hypoglycemic activities of Tolazamide.
TolazolineCarteolol may increase the hypotensive activities of Tolazoline.
TolbutamideCarteolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Carteolol.
TolmetinTolmetin may decrease the antihypertensive activities of Carteolol.
ToloxatoneToloxatone may increase the hypotensive activities of Carteolol.
TorasemideTorasemide may increase the hypotensive activities of Carteolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Carteolol.
TranilastTranilast may decrease the antihypertensive activities of Carteolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carteolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Carteolol.
TravoprostTravoprost may increase the hypotensive activities of Carteolol.
TrazodoneThe serum concentration of Carteolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Carteolol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Carteolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Carteolol.
TrichlormethiazideCarteolol may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Carteolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Carteolol.
TrimazosinCarteolol may increase the hypotensive activities of Trimazosin.
TrimethaphanCarteolol may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Carteolol.
TubocurarineTubocurarine may increase the bradycardic activities of Carteolol.
UdenafilUdenafil may increase the antihypertensive activities of Carteolol.
UnoprostoneCarteolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Carteolol.
ValsartanValsartan may increase the hypotensive activities of Carteolol.
VardenafilVardenafil may increase the antihypertensive activities of Carteolol.
VareniclineThe risk or severity of adverse effects can be increased when Carteolol is combined with Varenicline.
VenlafaxineThe metabolism of Carteolol can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Carteolol is combined with Verapamil.
VilanterolCarteolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Carteolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Carteolol can be increased when it is combined with Vortioxetine.
XylometazolineCarteolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Carteolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Carteolol.
ZileutonZileuton may decrease the antihypertensive activities of Carteolol.
ZimelidineThe serum concentration of Carteolol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Carteolol can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may decrease the antihypertensive activities of Carteolol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Wheeldon NM, McDevitt DG, Lipworth BJ: Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411-6. [PubMed:1349493 ]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107 ]
  3. Chidlow G, Melena J, Osborne NN: Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol. 2000 Jun;130(4):759-66. [PubMed:10864881 ]
  4. Floreani M, Froldi G, Quintieri L, Varani K, Borea PA, Dorigo MT, Dorigo P: In vitro evidence that carteolol is a nonconventional partial agonist of guinea pig cardiac beta1-adrenoceptors: a comparison with xamoterol. J Pharmacol Exp Ther. 2005 Dec;315(3):1386-95. Epub 2005 Sep 13. [PubMed:16160085 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Kudo S, Uchida M, Odomi M: Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol. 1997;52(6):479-85. [PubMed:9342584 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23